0.5mL//syringe
| 【GENERIC NAME】 |
| Influenza Vaccine（Split Virion）,Inactivated，Quadrivalent |
| 【ACTIVE INGREDIENTS】 |
| Hemagglutinin of prevalent strains of influenza virus in current year. |
| 【VACCINATION SUBJECTS】 |
| The vaccine is approved for use in people aged 3 and above, especially in vulnerable people and high risk population for influenza complications, such as children, the elderly, the weak and people in influenza epidemic areas. |
- 0.5mL//vial
- 0.5mL//syringe
Please read this instruction carefully and use under the guidance of physicians
[Drug Name]
Generic Name: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
English Name: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Chinese Pinyin: Sijia Liugan Bingdu Liejie Yimiao
[Constituents and Characters]
The vaccine is prepared from influenza virus type A and B prevalent strains recommended by WHO. The virus strains are inoculated in embryo eggs. After incubation, the virus liquid is harvested. The vaccine is prepared by inactivation, concentration, purification and splitting. The vaccine is a slightly opalescent liquid.
Active ingredients: Hemagglutinin of prevalent strains of influenza virus in current year. 0.5ml of the vaccine contains:
A/Victoria/2570/2019 (H1N1)pdm09-like virus…………….............15μɡ HA
A/Darwin/9/2021 (H3N2)-like virus……………………...................15μɡ HA
B/Austria/1359417/2021 (B/Victoria lineage)-like virus………........15μɡ HA
B/Phuket/3073/2013 (B/Yamagata lineage)-like viruss………...........15μɡ HA
Excipients: Na2HPO4, NaH2PO4, NaCl.
[Vaccination Subjects]
The vaccine is approved for use in people aged 3 years old and above, especially in vulnerable people and high risk population for influenza complications, such as children, the elderly, the weak and people in influenza epidemic areas.
[Function and Use]
After vaccination, the vaccine can stimulate the body to produce the immunity of anti-influenza virus; it is used for preventing influenza caused by vaccine-related type of influenza virus.
[Specifications]
0.5ml per vial (syringe), 0.5ml human dose for each use, contains 15μg HA of each type of influenza strains.
[Administration and Dosages]
1. Intramuscularly inject the vaccine in the region of the deltoid muscle of the upper arm.
2. People vaccinate the vaccine before or during the influenza pandemic season for prevention. Adult, children aged 3 years old and above should be vaccinated one dose of vaccine (0.5ml).
[Adverse Reactions]
A total of 3,045 subjects aged 3 years old and above participate in two clinical studies of this product in China, of which 1,095 subjects receive at least one dose of this vaccine. The safety observation of this product system is from the beginning of vaccination to 30 days after the whole vaccination, and the long-term safety observation of most subjects is from 31 days to 180 days after the whole vaccination.
According to the classification of adverse reactions recommended by the Council for International Organizations of Medical Sciences (CIOMS): very common (≥10%), common (1%-10%, including 1%), occasional (0.1%-1%, including 0.1%), rare (0.01%-0.1%, including 0.01%), very rare (< 0.01%), as described below:
1. Clinical trial
Systemic adverse reaction
Very common: fever;
Occasional: headache, fatigue, nausea, vomiting, diarrhea, cough, allergy, muscle pain;
Local adverse reactions
Common: pain, swelling;
Occasional: red, induration, pruritus.
2. Domestic clinical trials of similar products
Serious adverse reactions
Rare: anaphylactoid purpura.
3. Foreign clinical trial and post-market monitoring of similar products
The safety data of foreign clinical trial of similar products are summarized as follows:
Systemic adverse reactions
Very common: myalgia, headache, fatigue, discomfort, arthralgia, gastrointestinal symptoms, lethargy, irritability, loss of appetite;
Common: chills, fever;
Local adverse reactions
Very common: pain, redness, swelling;
Occasional: induration and ecchymosis;
Serious adverse reactions
Rare: systemic anaphylaxis.
The safety data obtained from foreign post-market monitoring are summarized as follows:
Digestive system: abdominal pain or discomfort, swelling of the mouth, throat and/or tongue;
Blood and lymphatic system: enlarged lymph nodes;
Infection and invasive diseases: injection site cellulitis, pharyngitis, rhinitis, tonsillitis;
Nervous system: convulsion, encephalomyelitis, facial paralysis, Guillain-Barre syndrome, myelitis, neuritis, sensory abnormalities, syncope;
Respiratory system: asthma, bronchospasm, dyspnea;
Cardiovascular system: tachycardia, vasculitis;
Vestibular system of inner ear: vertigo
Skin system: angioedema, erythema, swelling, pruritus, Stevens-Johnson syndrome, sweating, urticaria;
Eyes: conjunctivitis, eye pain, redness, swelling and eyelid swelling;
Immune system: anaphylactic shock, anaphylactoid purpura, hypersensitivity reaction, and serum sickness.
[Contraindications]
(1) Subjects with known hypersensitivity reactions to any components of the vaccine, including eggs, excipients, formaldehyde, Triton X-100.
(2) Subjects who have acute illness, serious chronic diseases, acute exacerbation of chronic disease, cold and fever.
(3) Subjects with a diagnosis of uncontrolled epilepsy or other nervous system progressive disease, and history of Guillain-Barre Syndrome.
If any of the above cases, prohibit use this product, and timely inform the doctor.
[Precautions]
(1) The vaccine should be administered with caution in family and individual with convulsions history, chronic disease, epilepsy history or allergies.
(2) If either of appearance abnormities exists, the vaccine should not be administered. Any crack in container, illegible label, expiration, turbidity or any lump floccule not dispersed after shaking in the container.
(3) Use immediately once the container is opened.
(4) The vaccine should be used within the shelf life stated on the label.
(5) Adrenaline should be available for first aid in case of serious anaphylactic reactions. The recipients should take a rest for at least 30 minutes on site after vaccination.
(6) Revaccination is prohibited if any neurological reaction occurs after vaccination.
(7) Subjects treated with immunoglobulin shall defer for at least one month for the vaccination with this vaccine.
(8) Intravenous injection of the vaccine is strictly prohibited.
(9) Do not be freezed or partially used.
(10) The vaccine shall not be mixed with other medical products and injected together in a syringe.
(11) Immunocompromised subjects or those who have any questions before use should consult and comply with the medical advice.
[Medication for Pregnant and Lactating Women]
Data from clinical trials of this product in pregnant and lactating women are not available.
[Drug Interactions]
If you are using or have recently used any other vaccine or drug, please inform your doctor.
The use of immunosuppressants may weaken the body's immune response to this product.
- UP：0.5mL//vial
- NEXT：NONE;
